269 related articles for article (PubMed ID: 24379124)
21. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures.
Brohawn PZ; Streicher K; Higgs BW; Morehouse C; Liu H; Illei G; Ranade K
Lupus; 2019 Nov; 28(13):1524-1533. PubMed ID: 31660791
[TBL] [Abstract][Full Text] [Related]
22. Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin.
Lambers WM; de Leeuw K; Doornbos-van der Meer B; Diercks GFH; Bootsma H; Westra J
Arthritis Res Ther; 2019 Dec; 21(1):260. PubMed ID: 31791398
[TBL] [Abstract][Full Text] [Related]
23. Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.
Vossenkämper A; Lutalo PM; Spencer J
Clin Exp Immunol; 2012 Jan; 167(1):7-14. PubMed ID: 22132879
[TBL] [Abstract][Full Text] [Related]
24. The Expression of BAFF Is Controlled by IRF Transcription Factors.
Sjöstrand M; Johansson A; Aqrawi L; Olsson T; Wahren-Herlenius M; Espinosa A
J Immunol; 2016 Jan; 196(1):91-6. PubMed ID: 26590315
[TBL] [Abstract][Full Text] [Related]
25. Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus.
Yuan Y; Kasar S; Underbayev C; Vollenweider D; Salerno E; Kotenko SV; Raveche E
Mol Immunol; 2012 Sep; 52(2):61-70. PubMed ID: 22578383
[TBL] [Abstract][Full Text] [Related]
26. Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN.
Dieudonné Y; Gies V; Guffroy A; Keime C; Bird AK; Liesveld J; Barnas JL; Poindron V; Douiri N; Soulas-Sprauel P; Martin T; Meffre E; Anolik JH; Korganow AS
J Autoimmun; 2019 Aug; 102():150-158. PubMed ID: 31085070
[TBL] [Abstract][Full Text] [Related]
27. Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.
Sriram U; Varghese L; Bennett HL; Jog NR; Shivers DK; Ning Y; Behrens EM; Caricchio R; Gallucci S
J Immunol; 2012 Jul; 189(1):80-91. PubMed ID: 22661089
[TBL] [Abstract][Full Text] [Related]
28. Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus.
Jones SA; Toh AE; Odobasic D; Oudin MA; Cheng Q; Lee JP; White SJ; Russ BE; Infantino S; Light A; Tarlinton DM; Harris J; Morand EF
Ann Rheum Dis; 2016 Apr; 75(4):739-47. PubMed ID: 26612340
[TBL] [Abstract][Full Text] [Related]
29. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.
Munroe ME; Lu R; Zhao YD; Fife DA; Robertson JM; Guthridge JM; Niewold TB; Tsokos GC; Keith MP; Harley JB; James JA
Ann Rheum Dis; 2016 Nov; 75(11):2014-2021. PubMed ID: 27088255
[TBL] [Abstract][Full Text] [Related]
30. Gender differences of B cell signature related to estrogen-induced IFI44L/BAFF in systemic lupus erythematosus.
Fan H; Zhao G; Ren D; Liu F; Dong G; Hou Y
Immunol Lett; 2017 Jan; 181():71-78. PubMed ID: 27923569
[TBL] [Abstract][Full Text] [Related]
31. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B.
Harigai M; Kawamoto M; Hara M; Kubota T; Kamatani N; Miyasaka N
J Immunol; 2008 Aug; 181(3):2211-9. PubMed ID: 18641361
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus.
Hillion S; Garaud S; Devauchelle V; Bordron A; Berthou C; Youinou P; Jamin C
Immunology; 2007 Nov; 122(3):371-80. PubMed ID: 17608810
[TBL] [Abstract][Full Text] [Related]
33. Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus.
Han BK; Wysham KD; Cain KC; Tyden H; Bengtsson AA; Lood C
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32444416
[TBL] [Abstract][Full Text] [Related]
34. Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells.
Hamilton JA; Wu Q; Yang P; Luo B; Liu S; Li J; L Mattheyses A; Sanz I; Chatham WW; Hsu HC; Mountz JD
J Immunol; 2018 Oct; 201(8):2203-2208. PubMed ID: 30201809
[TBL] [Abstract][Full Text] [Related]
35. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
[TBL] [Abstract][Full Text] [Related]
36. Expansion of bone marrow IFN-alpha-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-alpha in NZB bone marrow.
Lian ZX; Kikuchi K; Yang GX; Ansari AA; Ikehara S; Gershwin ME
J Immunol; 2004 Oct; 173(8):5283-9. PubMed ID: 15470074
[TBL] [Abstract][Full Text] [Related]
37. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
Wang H; Li T; Chen S; Gu Y; Ye S
Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
[TBL] [Abstract][Full Text] [Related]
38. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity.
Wu Q; Yang Q; Lourenco E; Sun H; Zhang Y
Arthritis Res Ther; 2011 Jun; 13(3):R88. PubMed ID: 21679442
[TBL] [Abstract][Full Text] [Related]
39. PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus.
Han X; Vesely MD; Yang W; Sanmamed MF; Badri T; Alawa J; López-Giráldez F; Gaule P; Lee SW; Zhang JP; Nie X; Nassar A; Boto A; Flies DB; Zheng L; Kim TK; Moeckel GW; McNiff JM; Chen L
Sci Transl Med; 2019 Dec; 11(522):. PubMed ID: 31826980
[TBL] [Abstract][Full Text] [Related]
40. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.
Matsuyama T; Kimura T; Kitagawa M; Pfeffer K; Kawakami T; Watanabe N; Kündig TM; Amakawa R; Kishihara K; Wakeham A
Cell; 1993 Oct; 75(1):83-97. PubMed ID: 8402903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
